Long-term safety and efficacy of alirocumab in South African patients with heterozygous familial hypercholesterolaemia: the ODYSSEY Open-Label Extension study.

CONCLUSIONS: Alirocumab effectively and safely reduced LDL-C in these patients.
PMID: 31512717 [PubMed - as supplied by publisher]

Source: Cardiovascular Journal of Africa - September 10, 2019 Category: Cardiology Authors: Blom DJ, Breedt J, Burgess LJ, Ebrahim IO, Ellis G, Soma P, van der Walt E, Naidoo P, van Tonder A, Raal FJ Tags: Cardiovasc J Afr Source Type: research